|Bid||145.00 x 20000|
|Ask||146.00 x 20000|
|Day's Range||144.00 - 144.00|
|52 Week Range||79.50 - 146.00|
|Beta (5Y Monthly)||0.42|
|PE Ratio (TTM)||49.66|
|Forward Dividend & Yield||1.40 (0.96%)|
|Ex-Dividend Date||Nov 06, 2019|
|1y Target Est||N/A|
Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, is investigating potential claims against certain officers and directors of ResMed, Inc. (NYSE: RMD) on behalf of long-term stockholders.
Shareholder rights law firm Robbins LLP is investigating whether certain officers and directors of ResMed Inc. (NYSE: RMD) breached their fiduciary duties to shareholders. ResMed develops, manufactures, and markets medical equipment for the treatment of sleep disordered breathing.
ResMed (NYSE: RMD) (ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2020 on Thursday, January 30, 2020, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this call.
ResMed (NYSE: RMD, ASX: RMD) today announced that Mick Farrell, chief executive officer, will present at the 38th Annual J.P. Morgan Annual Healthcare Conference on Monday, January 13, 2020, beginning at approximately 8:30 a.m. (Pacific Standard Time) at Westin St. Francis in San Francisco, CA.